Structure via PubChem · Public domain (PubChem)
resiquimod
Sign in to saveAlso known as R-848, R848, R 848
Resiquimod (R-848) is a drug that acts as an immune response modifier, and has antiviral and antitumour activity. It is used as a topical gel in the treatment of skin lesions such as those caused by the herpes simplex virus and cutaneous T cell lymphoma, and as an adjuvant to increase the effectiveness of vaccines. In an animal disease model, systemic administration of resiquimod-loaded nanoparticles has been shown to improve response rates to cancer immunotherapy with a checkpoint inhibitor through stimulation of tumor-associated macrophages. It has several mechanisms of action, being both an
In the Vinony graph
Vinony's link graph records 98 inbound references to resiquimod, and connects out to chemotherapy, dermatology and nucleoside analogue.
Vinony files it under Anti-herpes virus drugs, Antineoplastic drugs and Chemical pages without DrugBank identifier.
Vinony links it to 6 Wikipedia language editions.
Chemical data
- Formula
- C17H22N4O2
- Molecular weight
- 314.4 g/mol
- IUPAC name
- 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol
- SMILES
- CCOCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N
- InChIKey
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N
- XLogP
- 1.3
- Polar surface area
- 86.2 Ų
- H-bond donors
- 2
- H-bond acceptors
- 5
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 2
- Molecule type
- Small molecule
- Indications
- cutaneous melanoma, melanoma, metastatic melanoma, basal cell carcinoma
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 314.174
Show 3 more facts
- Commons category
- Resiquimod
- chemical formula
- C₁₇H₂₂N₄O₂
- canonical SMILES
- CCOCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Resiquimod (R-848) is a drug that acts as an immune response modifier, and has antiviral and antitumour activity. It is used as a topical gel in the treatment of skin lesions such as those caused by the herpes simplex virus and cutaneous T cell lymphoma, and as an adjuvant to increase the effectiveness of vaccines. In an animal disease model, systemic administration of resiquimod-loaded nanoparticles has been shown to improve response rates to cancer immunotherapy with a checkpoint inhibitor through stimulation of tumor-associated macrophages. It has several mechanisms of action, being both an agonist for toll-like receptor 7 and 8, and an upregulator of the opioid growth factor receptor. On 28 April 2016, orphan designation (EU/3/16/1653) was granted by the European Commission to Galderma R&D, France for resiquimod to be used in the treatment of cutaneous T-cell lymphoma.
== See also == Imiquimod Gardiquimod
Excerpted from Wikipedia’s “resiquimod” article, available under the CC BY-SA 4.0 licence.